Diabetes Pharmacology

Disclaimer: These notes are designed to provide the key points of each topic and may not contain all necessary information. Every effort is made to ensure this content is up to date and accurate at the time of writing. No liability is assumed for the content or its relation to current standards and practices. This should not replace comprehensive nursing educational resources.

Diabetes pathophysiology and nursing review

- Type 1 diabetes is an autoimmune disorder where the body's immune system attacks and destroys the insulin-producing beta cells in the pancreas
- Type 2 diabetes is primarily a result of insulin resistance, where the body's cells do not respond effectively to insulin
- Hypoglycemia is treated with oral glucose, IV dextrose, or IM glucagon
- The body releases insulin in response to a high serum glucose level and glucagon when low
- Treatment of DM is monitored via blood glucose and A1C levels
- DKA and HHS are treated with insulin and fluids
- Complications include diabetic retinopathy, nephropathy, neuropathy, atherosclerosis, PVD
- Educate patients on lifestyle modifications

Drug class: Insulin

Rapid	Lispro, Aspart	15-30 min	3-5 hrs	Used for meal coverage
Short	Regular (Humalin R)	0.5-1 hr	5-10 hrs	IV infusion
Intermediate	NPH (Humalin N)	1-2 hr	12-24 hrs	AKA Isophene
Long	Glargine, Detemir	1-4 hr	24 hrs	Basal coverage

- MOA: Insulin stimulates cellular uptake of glucose and promotes conversion of glucose into glycogen
- Indications: Diabetes
 - Also used with glucose to treat acute hyperkalemia
- Only given parenterally
- SE/AE: Hypoglycemia, hypokalemia
- Multiple insulins may be used to provide for basal coverage in addition to prandial coverage
- When drawing NPH with a short acting, draw up the short acting insulin first
- Insulin is stored at refrigerated temperature
 - o Once in use it can be used for thirty days and can be stored at room temperature
- Goal is a hemoglobin A1C of less than 7%
- If the insulin causes hypoglycemia treat with oral glucose or IV glucose / IM glucagon
- Educate patient and family to rotate injection sites to prevent lipodystrophy
- Advise patient to wear a medical alert bracelet
- Teach signs and symptoms of hypoglycemia and hyperglycemia
- Sliding scale is sometimes used to calculate dose for insulin
 - This prescribes a specific dose based upon the blood glucose level
- Assess blood glucose level before and after insulin administration
 - Normal is 70-110
- IV insulin infusion is considered high risk and is usually only given in the ED/ICU

Drug class: Biguanides

- Drug:
 - Metformin (Glucophage)
- MOA: Blocks glucose production in the liver and increases insulin sensitivity
- Indications: Diabetes
- Off-label use includes PCOS
- Black Box warning: Can cause lactic acidosis
- SE/AE: GI upset, worse upon starting treatment
- Alcohol should be avoided
- First line agent for type two diabetes

Drug class: Glucagon-like peptide-1 receptor agonists (GLP-1 agonists)

- Drugs:
 - Exentide (Byetta)
 - Liraglutide (Victoza)
 - Dulaglutide (Trulicity)
 - Semaglutide (Ozempic)
- MOA: Increases the effects of incretin which stimulates release of insulin and blocks release of glucagon
- Indications: Diabetes
 - May also be used for weight loss
- Black Box warning: Thyroid C-cell cancer risk
- SE/AE: GI effects, increased HR
- Subcutaneous only
- Often used as a second line agent following metformin

Drug class: Sulfonylureas

- Drug:
 - o Glipizide (Glucotrol)
 - o Glimepiride
- MOA: Stimulates the release of insulin
- Indications: Diabetes
- SE/AE: Hypoglycemia, weight gain
- Caution for a disulfiram like reaction when combined with alcohol

Drug class: Meglitinides

- Drug:
 - Repaglinide
- MOA: Stimulate the release of insulin
- Indications: Diabetes
- SE/AE: Hypoglycemia
 - Should be followed by a meal to avoid this

Drug class: Thiazolidinediones

- Drugs:
 - Rosiglitazone (Avandia)
 - Pioglitazone (Actos)
- MOA: Increases insulin sensitivity
- Indications: Diabetes
- SE/AE: Weight gain
- Black Box warning: Can cause or exacerbate heart failure
- Contraindicated in pregnancy, heart failure, high risk for fractures, and acute liver failure

Drug class: Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors)

- Drugs:
 - Linagliptin (Tradjenta)
 - Sitagliptin (Januvia)
- MOA: Block the breakdown of incretin, which stimulates release of insulin and blocks release of glucagon
- Indications: Diabetes

Drug class: Sodium-glucose co-transporter 2 inhibitors (SGLT-2 inhibitors)

- Drugs:
 - Dapagliflozin (Farxiga)
 - Empagliflozin (Jardiance)
- MOA: Promote urinary glucose excretion; it also reduces cardiac preload and afterload
- Indications: Diabetes, chronic kidney disease, and heart failure
- SE/AE: UTI in females and weight loss

Drug class: Alpha glucosidase inhibitors

- Drug:
 - Acarbose
- MOA: Slows the digestion of carbohydrates
- Indications: Diabetes
- SE/AE: GI effects
- Take at the start of the meal

References

- Adams, M., Holland, N. & Chang, S. (2023). *Pharmacology for nurses; a pathophysiologic approach.*Pearson
- Burchum, J., & Rosenthal, L. (2022). Lehne's pharmacology for nursing care. Elsevier
- Mccuistion, L., Vuljoin-DiMaggio, K., Winton, M., & Yeager, J. (2023) *Pharmacology: A patient centered nursing process approach*. Elsevier
- Wexler, D. (2022) Initial management of hyperglycemia in adults with type 2 diabetes mellitus.

www.uptodate.com